Our Innovative Aptamer Platform Technology
The Possibilities Are Endless
Our platform technology, based on nucleic acid aptamers, is exceptionally well suited for the development of long-acting (Q16-24w), highly specific ocular therapeutics. The company possesses a rich patent portfolio that includes aptamers that bind and inhibit important and novel molecular targets in the eye. The Drive team also possesses the technological know-how to rapidly develop novel ligands to novel targets.